CCT400028 |
|
Catalog No.GC80921
|
CCT400028 is a PROTACs -class degrader that targets the Aurora A (AURKA) kinase.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
In Vitro, CCT400028 (0.001-10 μM; 0-24 h) shows no hook effect, potently degrades Aurora A in MV4-11 human pediatric leukemia cells, with a DC50 of 29 nM at 6 h and a DCmax of 85%; it also induces potent and sustained (24 h) Aurora A degradation in human pediatric neuroblastoma Kelly cells[1]. The Aurora A degradation activity of CCT400028 (1 μM; 4 h) in human pediatric neuroblastoma Kelly cells can be blocked by proteasome function inhibitors, Cullin ring ligase activity inhibitors, CRBN-binding inhibitors, and Aurora A-binding inhibitors (inhibitors require 2 h of pre-treatment)[1]. CCT400028 (0.01-10 μM; 72 h) inhibits the viability of human pediatric leukemia cells MV4-11, with a GI50 of 310 nM[1].
References:
[1]. O'Hanlon JA, et al. Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC JB170 to CCT400028, an In Vitro Degrader Chemical Probe. J Med Chem. 2026 Jan 22;69(2):1552-1567.
| Cas No. | SDF | ||
| Formula | C47H49ClFN7O7 | M.Wt | 878.39 |
| Solubility | DMSO: 100 mg/mL (113.84 mM; Need ultrasonic) | Storage | Store at 4°C, away from moisture |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1384 mL | 5.6922 mL | 11.3845 mL |
| 5 mM | 227.7 μL | 1.1384 mL | 2.2769 mL |
| 10 mM | 113.8 μL | 569.2 μL | 1.1384 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















